The European Medicine Agency (EMA) has also approved multiple ALK inhibitors including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib for treatment of ALK-aberrant NSCLC and crizotinib for unresectable ALK-aberrant IMT and ALCL in children and adolescents between the ages of 6 and 1840. Here, ALK is linked to inflammatory myofibroblastic tumor.